OR WAIT null SECS
September 08, 2020
Industry leaders insist they will maintain high standards for clinical trials and regulatory submissions for new vaccines and therapeutics to combat COVID-19.
September 03, 2020
BIO leaders urge biopharmaceutical companies to apply scientific principles in seeking drug and vaccine approvals.
Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain.
Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations.
A device manufacturing process must be carefully designed in the early stages of development to ensure success in commercial manufacturing.
September 02, 2020
Amid high expectations for a vaccine, bio/pharma readies capacity, weighs pressures.
The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.
The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.
Innovative approaches to drug screening—such as evaluation to identify the optimal solid state of a molecule and in-vitro characterization to establish the optimal solid state of a molecule and the ideal bioavailability-enhancing technology—can help drug developers meet accelerated development timelines while managing risk.
End-user considerations are becoming increasingly important as they can provide a lot of value and help to ensure commercial success of a drug.
